长期口服降纤治疗对缺血性脑卒中患者预后的影响

The Effect of Long-term Fibrigoen-depleting on The Carotid Aherosclerosis and Cerebral Infarction

目的评价口服降纤治疗在缺血性脑卒中患者二级预防中的作用。方法将入选120例患者分为两组,对照组给予常规的神经内科治疗,试验组在此基础上加用蚓激酶60万单位,口服,3次/d,随访观察时间为1年,检测治疗前及治疗1年后血浆纤维蛋白原的水平(Fg),运用彩色超声多普勒仪记录治疗前后颈动脉斑块体积,观察治疗后的脑血管事件发生率。结果与对照组相比,试验组治疗前后Fg,左右颈动脉斑块体积的变化具有统计学意义(P<0.05)。与对照组相比,试验组治疗后脑血管事件发生率降低,但没有达到统计学意义。结论缺血性脑卒中患者长期口服蚓激酶降纤治疗可有效降低血浆纤维蛋白原,改善颈动脉粥样硬化,有效降低脑血管事件发生率。

Objective To assess the role of fibrinogen-depleting therapy in the second prevention of ischemic stroke.Methods 120 patients with ischemic stroke were divided into either control group that received a conventional neurology treatment or fibrinogen-depleting group that also received Lumbrokinase（600000 units,oral,three times per day）.They were followed up for 12 months.The level of plasma Fg was detected before and after treatment.To detect the plaque volume by the color Doppler ultrasound instrument before and after treatment.The incidence rate of cerebrovascular events was calculated after treatment.Results Contrasted with the control group,changes of Fg and both sides plaque volume had significant differences（P〈0.05） in the fibrinogen-depleting groups.The incidence rate of the cerebral vascular events was different between the two groups,but did not reach statistical significance.Conclusion Long term oral fibrinogen-depleting therapy in patients with ischemic stroke can significantly reduce the Fg levels in plasma,improve the prognosis of carotid atherosclerosis and reduce the incidence rate of cerebrovascular events.